替利珠单抗-话题@MedSci

#替利珠单抗#

16篇内容 | 1277人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2083110, encodeId=3dc72083110f2, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, objectType=article, longId=735782, objectId=d1d6e3578230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1d6e3578230, replyNumber=0, likeNumber=103, createdTime=2023-04-05, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1d6e3578230, moduleTitle=IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1d6e3578230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083107, encodeId=4dc3208310e54, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, objectType=article, longId=727300, objectId=7f29e2730032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f29e2730032, replyNumber=0, likeNumber=98, createdTime=2022-11-01, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f29e2730032, moduleTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f29e2730032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083104, encodeId=fc0020831044f, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效, objectType=article, longId=301398, objectId=90fb30139881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90fb30139881, replyNumber=0, likeNumber=130, createdTime=2022-07-11, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90fb30139881, moduleTitle=J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90fb30139881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083109, encodeId=c34a2083109d1, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, objectType=article, longId=731375, objectId=9d30e31375a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d30e31375a9, replyNumber=0, likeNumber=150, createdTime=2022-09-03, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d30e31375a9, moduleTitle=一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d30e31375a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083108, encodeId=ef8d208310824, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, objectType=article, longId=728685, objectId=6d07e286855f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d07e286855f, replyNumber=0, likeNumber=117, createdTime=2022-09-14, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d07e286855f, moduleTitle=Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d07e286855f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083106, encodeId=f6c7208310615, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, objectType=article, longId=302277, objectId=26843022e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26843022e794, replyNumber=0, likeNumber=101, createdTime=2023-01-28, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26843022e794, moduleTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26843022e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083103, encodeId=b4372083103d7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=91, createdTime=2023-01-19, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083105, encodeId=0d0a20831058a, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, objectType=article, longId=301718, objectId=f3b0301e18e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b0301e18e1, replyNumber=0, likeNumber=100, createdTime=2022-04-27, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b0301e18e1, moduleTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3b0301e18e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083099, encodeId=360b208309972, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), objectType=article, longId=212511, objectId=4d8b21251198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8b21251198, replyNumber=0, likeNumber=151, createdTime=2021-10-18, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8b21251198, moduleTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8b21251198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083100, encodeId=50142083100d1, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, objectType=article, longId=214763, objectId=e0a7214e632f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a7214e632f, replyNumber=0, likeNumber=103, createdTime=2021-11-11, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a7214e632f, moduleTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a7214e632f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083101, encodeId=43662083101ab, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=阿替利珠单抗对于非小细胞癌的治疗效果如何？, objectType=article, longId=214866, objectId=11fe2148660c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11fe2148660c, replyNumber=0, likeNumber=90, createdTime=2022-02-12, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11fe2148660c, moduleTitle=阿替利珠单抗对于非小细胞癌的治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11fe2148660c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083102, encodeId=4dfa2083102f7, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, objectType=article, longId=214989, objectId=b1e72149892f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e72149892f, replyNumber=0, likeNumber=140, createdTime=2021-08-18, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e72149892f, moduleTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1e72149892f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083097, encodeId=17b0208309e86, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, objectType=article, longId=202634, objectId=735d202634e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=735d202634e5, replyNumber=0, likeNumber=99, createdTime=2021-01-22, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=735d202634e5, moduleTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=735d202634e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083098, encodeId=1a6d208309843, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=ASCO GU 2021: 阿替利珠单抗一线治疗局晚或转移的尿路上皮癌结果发布（IMvigor130研究）, objectType=article, longId=207204, objectId=d52d20e20494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d52d20e20494, replyNumber=0, likeNumber=81, createdTime=2022-01-25, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d52d20e20494, moduleTitle=ASCO GU 2021: 阿替利珠单抗一线治疗局晚或转移的尿路上皮癌结果发布（IMvigor130研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d52d20e20494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083096, encodeId=20d7208309662, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=NEJM：替利珠单抗与1型糖尿病风险, objectType=article, longId=177708, objectId=25901e770893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25901e770893, replyNumber=0, likeNumber=87, createdTime=2020-07-15, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25901e770893, moduleTitle=NEJM：替利珠单抗与1型糖尿病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25901e770893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2083095, encodeId=fece208309533, content=<a href='/topic/show?id=f1dc603355d' target=_blank style='color:#2F92EE;'>#替利珠单抗#</a>, objectTitle=J Thorac Oncol：OAK研究再分析：NSCLC进展后继续阿替利珠单抗治疗仍可获益, objectType=article, longId=156035, objectId=f0fb15603581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0fb15603581, replyNumber=0, likeNumber=131, createdTime=2019-05-19, rootId=0, userName=ms1779634646866130, userId=7a322500193, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0fb15603581, moduleTitle=J Thorac Oncol：OAK研究再分析：NSCLC进展后继续阿替利珠单抗治疗仍可获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0fb15603581)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

替利珠单抗

2020-05-29

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

IMpower010研究生存数据首次公布，夯实阿替利珠单抗为标准辅助治疗方案！| WCLC 2022速递

2023-04-05

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC

2022-11-01

智慧医人 (审核中...)

前往app查看评论内容

#替利珠单抗#

J Thorac Oncol：5项RCT研究合并分析表明质子泵抑制剂(PPIs)使用可降低atezolizumab（阿替利珠单抗）治疗的疗效

2022-07-11

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

一线治疗晚期肝癌哪家强？《柳叶刀肿瘤学》发布卡博替尼+阿替利珠单抗 vs 索拉非尼III期临床结果

2022-09-03

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

Lancet Oncol：FOLFOXIRI联合贝伐单抗±阿替利珠单抗治疗转移性结直肠癌

2022-09-14

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）

2023-01-28

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2023-01-19

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）

2022-04-27

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

2021-10-18

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150

2021-11-11

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

阿替利珠单抗对于非小细胞癌的治疗效果如何？

2022-02-12

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效

2021-08-18

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌

2021-01-22

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

ASCO GU 2021: 阿替利珠单抗一线治疗局晚或转移的尿路上皮癌结果发布（IMvigor130研究）

2022-01-25

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

NEJM：替利珠单抗与1型糖尿病风险

2020-07-15

ms1779634646866130 (审核中...)

前往app查看评论内容

#替利珠单抗#

J Thorac Oncol：OAK研究再分析：NSCLC进展后继续阿替利珠单抗治疗仍可获益

2019-05-19

科室
- - 订阅+
  - 更多科室
工具
服务